NDAOPHTHALMICSOLUTION/DROPS
Approved
Sep 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
11
Mechanism of Action
active, direct H1-receptor antagonist and an inhibitor of the release of histamine from mast cells.
Clinical Trials (5)
Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)
Started Jan 2013
617 enrolled
Seasonal Allergic Rhinitis
Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis
Started Dec 2011
606 enrolled
Seasonal Allergic Rhinitis
Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses
Started May 2011
24 enrolled
Allergic Conjunctivitis
The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer
Started May 2011
40 enrolled
Allergic Conjunctivitis
A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft
Started Apr 2011
25 enrolled
Allergic Conjunctivitis